| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
FTT-5 targets the endosomal membrane, undergoing protonation in the acidic endosomal environment, which promotes endosomal escape of mRNA and facilitates protein expression in target cells. It has no direct protein target but serves as a delivery vehicle component.
|
|---|---|
| ln Vitro |
In vitro, FTT-5 demonstrates efficient transfection of long mRNA into various cell lines when formulated into LNPs. It enables high levels of protein expression with low cytotoxicity compared to other lipid-like compounds. Cytotoxicity assessments show minimal reduction in cell viability at effective concentrations.
|
| ln Vivo |
In vivo, FTT-5 enables efficient delivery of long mRNA in animal models when incorporated into LNPs. It has been used for in vivo base editing and mRNA-based therapeutic applications. Studies demonstrate successful delivery of mRNA coding for therapeutic proteins such as erythropoietin (EPO) following intravenous administration.
|
| Enzyme Assay |
For non-cellular evaluation, the pKa of FTT-5 is determined by titration in liposomal suspensions. The compound is dissolved in DMSO and added to buffer solutions, and fluorescence changes of a pH-sensitive dye are monitored to calculate the apparent pKa, which influences endosomal escape efficiency.
|
| Cell Assay |
For cell-based assays, adherent cells (e.g., HeLa, HEK-293) are seeded in 96-well plates and treated with FTT-5 LNPs encapsulating reporter mRNA (e.g., luciferase or GFP). After 24-48 hours, transfection efficiency is measured by luminescence or fluorescence. Cytotoxicity is assessed by MTT or CellTiter-Glo assays, comparing treated cells to untreated controls.
|
| Animal Protocol |
For in vivo evaluation, female BALB/c mice are intravenously injected with FTT-5 LNPs encapsulating mRNA encoding a reporter protein (e.g., luciferase or erythropoietin). Blood samples are collected at various time points post-injection to measure protein expression. Organs (liver, spleen, lung, kidney) are harvested for ex vivo imaging or protein quantification to determine biodistribution and transfection efficiency.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for FTT-5 as a standalone compound are not available. When formulated into LNPs, the encapsulated mRNA exhibits a circulation half-life of several hours, with predominant accumulation in the liver and spleen. The lipid component itself is expected to be cleared through metabolic pathways.
|
| Toxicity/Toxicokinetics |
Toxicity data specific to FTT-5 are limited. In LNP-formulated studies, no significant acute toxicity or adverse effects have been reported at effective doses. In vitro cytotoxicity assessments in multiple cell lines show a favorable safety profile with IC50 values significantly higher than effective transfection concentrations. No formal toxicology studies have been published.
|
| References | |
| Additional Infomation |
FTT-5 is a research-grade ionizable lipid for non-viral mRNA delivery, not approved for human therapy. It is particularly valuable for gene editing applications such as CRISPR-Cas9. Its structure is optimized for long mRNA delivery, making it distinct from lipids designed for siRNA or small oligonucleotides. No clinical trials are registered for FTT-5.
|
| Molecular Formula |
C120H222N6O15
|
|---|---|
| Molecular Weight |
1989.07791852951
|
| Exact Mass |
1988.682
|
| CAS # |
2328129-27-5
|
| PubChem CID |
147104571
|
| Appearance |
Colorless to light yellow liquid
|
| LogP |
34.7
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
111
|
| Heavy Atom Count |
141
|
| Complexity |
2470
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCC(CCC)OC(=O)CCCCCCCCN(CCCCCCCCC(=O)OC(CCC)CCCC)CCCNC(=O)C1=CC(=CC(=C1)C(=O)NCCCN(CCCCCCCCC(=O)OC(CCC)CCCC)CCCCCCCCC(=O)OC(CCC)CCCC)C(=O)NCCCN(CCCCCCCCC(=O)OC(CCC)CCCC)CCCCCCCCC(=O)OC(CCC)CCCC
|
| InChi Key |
BLHSRXBNFPZCBY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C120H222N6O15/c1-13-25-76-106(70-19-7)136-112(127)82-55-43-31-37-49-61-91-124(92-62-50-38-32-44-56-83-113(128)137-107(71-20-8)77-26-14-2)97-67-88-121-118(133)103-100-104(119(134)122-89-68-98-125(93-63-51-39-33-45-57-84-114(129)138-108(72-21-9)78-27-15-3)94-64-52-40-34-46-58-85-115(130)139-109(73-22-10)79-28-16-4)102-105(101-103)120(135)123-90-69-99-126(95-65-53-41-35-47-59-86-116(131)140-110(74-23-11)80-29-17-5)96-66-54-42-36-48-60-87-117(132)141-111(75-24-12)81-30-18-6/h100-102,106-111H,13-99H2,1-12H3,(H,121,133)(H,122,134)(H,123,135)
|
| Chemical Name |
octan-4-yl 9-[3-[[3,5-bis[3-[bis(9-octan-4-yloxy-9-oxononyl)amino]propylcarbamoyl]benzoyl]amino]propyl-(9-octan-4-yloxy-9-oxononyl)amino]nonanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~25.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (1.26 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (1.26 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (1.26 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.5027 mL | 2.5137 mL | 5.0274 mL | |
| 5 mM | 0.1005 mL | 0.5027 mL | 1.0055 mL | |
| 10 mM | 0.0503 mL | 0.2514 mL | 0.5027 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
